Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;53(2):233-238.
doi: 10.1111/cea.14267. Epub 2022 Dec 16.

Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study)

Takeshi Nakahara  1 , Kenji Izuhara  2 , Daisuke Onozuka  3 , Hidehisa Saeki  4 , Satoshi Nunomura  2 , Motoi Takenaka  5 , Mai Matsumoto  5 , Yoko Kataoka  6 , Rai Fujimoto  6 , Sakae Kaneko  7 , Eishin Morita  7 , Akio Tanaka  8 , Michihiro Hide  8 , Tatsuro Okano  9 , Tomomitsu Miyagaki  9 , Natsuko Aoki  10 , Kimiko Nakajima  10 , Susumu Ichiyama  4 , Makiko Kido-Nakahara  1 , Kyoko Tonomura  11 , Yukinobu Nakagawa  11 , Risa Tamagawa-Mineoka  12 , Koji Masuda  12 , Takuya Takeichi  13 , Masashi Akiyama  13 , Yozo Ishiuji  14 , Michie Katsuta  14 , Yuki Kinoshita  15 , Chiharu Tateishi  15 , Aya Yamamoto  16 , Akimichi Morita  16 , Haruna Matsuda-Hirose  17 , Yutaka Hatano  17 , Hiroshi Kawasaki  18 , Keiji Tanese  18 , Mamitaro Ohtsuki  19 , Koji Kamiya  19 , Yudai Kabata  20 , Riichiro Abe  20 , Hiroshi Mitsui  21 , Tatsuyoshi Kawamura  21 , Gaku Tsuji  1 , Norito Katoh  12 , Masutaka Furue  1
Affiliations

Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study)

Takeshi Nakahara et al. Clin Exp Allergy. 2023 Feb.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Simpson EL, Bieber T, Guttman-Yassky E, et al. SOLO 1 and SOLO 2 investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
    1. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44-56.
    1. Nakahara T, Kido-Nakahara M, Onozuka D, et al. Efficacy of dupilumab for atopic dermatitis according to clinical course and clinical findings: a multicentre retrospective study. Acta Derm Venereol. 2021;101(11):adv00586.
    1. Kamata M, Tada Y. A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov. 2021;1(3):100042.
    1. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475-1482.

Publication types

MeSH terms

LinkOut - more resources